Arcutis Biotherapeutics. has been granted a patent for a topical pharmaceutical composition aimed at treating alopecia areata. The composition includes SHR0302 or spironolactone, with specific particle size requirements, and utilizes silicones like dimethicone for effective administration to the pilosebaceous unit. GlobalData’s report on Arcutis Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Arcutis Biotherapeutics, was a key innovation area identified from patents. Arcutis Biotherapeutics's grant share as of July 2024 was 21%. Grant share is based on the ratio of number of grants to total number of patents.
Topical treatment for alopecia areata using shr0302
The granted patent US12053481B2 outlines a method for treating alopecia areata and other hair loss conditions through the topical administration of a pharmaceutical composition. This composition includes a therapeutically effective amount of SHR0302 or its pharmaceutically acceptable salt, characterized by a primary particle size distribution with a D90 value of less than 20 µm. Additionally, the formulation incorporates a silicone, specifically dimethicone or cyclomethicone. The method emphasizes the delivery of SHR0302 to the pilosebaceous unit, achieving dermal penetration of at least 1 mm. The composition is typically presented as a suspension and contains SHR0302 in concentrations ranging from 0.10% w/w to 5% w/w.
Further claims detail the specific particle size distributions of SHR0302, with options for D90 values of less than 10 µm or 5 µm, and D50 and D10 values of less than 1.0 µm and 0.50 µm, respectively. The patent also encompasses treatment for various hair loss conditions, including alopecia, androgenic hair loss, hypotrichosis, and telogen effluvium, reinforcing the versatility of the method. Overall, the claims provide a comprehensive framework for the formulation and application of SHR0302 in addressing hair loss, highlighting its potential effectiveness in dermatological treatments.
To know more about GlobalData’s detailed insights on Arcutis Biotherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
